{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T23:39:10Z","timestamp":1779147550766,"version":"3.51.4"},"reference-count":29,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T00:00:00Z","timestamp":1557187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Objectives: To investigate pivmecillinam\u00b4s efficacy in uncomplicated lower urinary tract infection (UTI) caused by Staphylococcus saprophyticus\u2014considered non-susceptible to mecillinam. Methods: Participants with confirmed UTIs caused by S. saprophyticus from four randomized controlled trials, where pivmecillinam was empirically given to females with symptoms of UTIs. The primary outcome was defined as a cumulative clinical effect\u2014symptom resolution during the first eight days of therapy, without a recurrence of UTI symptoms in the long-term follow-up (approximately four weeks). Secondary outcomes included the bacteriological effect\u2014elimination of the causative agent, with or without new uropathogenic bacteria present in the first control urine sample. Significant bacteriuria was defined as \u2265103 bacteria\/mL. The antibiotic susceptibility testing was done by disc diffusion methodology, according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST). Results: Seventy-four females (18\u201355 years) were empirically treated with pivmecillinam for UTIs caused by S. saphrophyticus (mean age 25 years; standard deviation (SD) 5.8). The cumulative clinical effect was 53\/74 (72%), and the bacteriological effect was 51\/59 (86%). Conclusion: Pivmecillinam showed a high clinical and bacteriological effect in UTIs caused by S. saprophyticus in these four clinical trials. The characterization of non-susceptibility for mecillinam regarding the treatment of UTIs caused by this common pathogen may need to be revised.<\/jats:p>","DOI":"10.3390\/antibiotics8020057","type":"journal-article","created":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T11:22:35Z","timestamp":1557400955000},"page":"57","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Pivmecillinam for Uncomplicated Lower Urinary Tract Infections Caused by Staphylococcus saprophyticus\u2014Cumulative Observational Data from Four Recent Clinical Studies"],"prefix":"10.3390","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0670-9996","authenticated-orcid":false,"given":"Filip","family":"Jans\u00e5ker","sequence":"first","affiliation":[{"name":"Department of Clinical Microbiology, Hvidovre Hospital, University of Copenhagen, 2650 Hvidovre, Denmark"},{"name":"Department of Clinical Microbiology, Rigshospitalet, University of Copenhagen, 2100 Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Bollestad","sequence":"additional","affiliation":[{"name":"Division of Medicine, Stavanger University Hospital, 4068 Stavanger, Norway"},{"name":"Antibiotic Centre of Primary Care, Department of General Practice, Institute of Health and Society, University of Oslo, 0318 Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8947-2914","authenticated-orcid":false,"given":"Ingvild","family":"Vik","sequence":"additional","affiliation":[{"name":"Antibiotic Centre of Primary Care, Department of General Practice, Institute of Health and Society, University of Oslo, 0318 Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morten","family":"Lindb\u00e6k","sequence":"additional","affiliation":[{"name":"Antibiotic Centre of Primary Care, Department of General Practice, Institute of Health and Society, University of Oslo, 0318 Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0969-0063","authenticated-orcid":false,"given":"Lars","family":"Bjerrum","sequence":"additional","affiliation":[{"name":"Section of General Practice and Research Unit of General Practice, Department of Public Health, University of Copenhagen, 1014 Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels","family":"Frimodt-M\u00f8ller","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, Rigshospitalet, University of Copenhagen, 2100 Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8699-9956","authenticated-orcid":false,"given":"Jenny","family":"Knudsen","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, Hvidovre Hospital, University of Copenhagen, 2650 Hvidovre, Denmark"},{"name":"Department of Clinical Microbiology, Rigshospitalet, University of Copenhagen, 2100 Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2019,5,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/newbio236135a0","article-title":"6-amidinopenicillanic acids\u2014A new group of antibiotics","volume":"236","author":"Lund","year":"1972","journal-title":"Nat. New Biol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/jac\/dkt368","article-title":"Emerging clinical role of pivmecillinam in the treatment of urinary tract infection in the context of multidrug-resistant bacteria","volume":"69","author":"Dewar","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1093\/jac\/46.suppl_1.35","article-title":"Pivmecillinam in the treatment of urinary tract infections","volume":"46","author":"Nicolle","year":"2000","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000237814","article-title":"Urinary excretion of mecillinam by volunteers receiving film-coated tablets of pivmecillinam hydrochloride","volume":"25","author":"Anderson","year":"1979","journal-title":"Chemotherapy"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1469-0691.2004.00737.x","article-title":"Urinary concentrations and urine ex-vivo effect of mecillinam and sulphamethizole","volume":"10","author":"Kerrn","year":"2004","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_6","unstructured":"NORM\/NORM-VET 2017 (2019, April 09). Usage of Antimicrobial Agents and Occurrence of Antimicrobial Resistance in Norway. Available online: www.antibiotikaresistens.no."},{"key":"ref_7","unstructured":"DANMAP 2017 (2019, April 09). Use of Antimicrobial Agents and Occurrence of Antimicrobial Resistance in Bacteria from Food Animals, Food and Humans in Denmark. Available online: www.danmap.org."},{"key":"ref_8","unstructured":"SWEDRES-SVARM 2017 (2019, April 09). Consumption of Antibiotics and Occurrence of Resistance in Sweden. Available online: www.folkhalsomyndigheten.se."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1093\/jac\/dky230","article-title":"Clinical and bacteriological efficacy of pivmecillinam treatment for uncomplicated urinary tract infections caused by ESBL-producing Escherichia coli: A prospective, multicentre, observational cohort study","volume":"73","author":"Bollestad","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/jac\/dkt404","article-title":"Clinical and bacteriological effects of pivmecillinam for ESBL-producing Escherichia coli or Klebsiella pneumoniae in urinary tract infections","volume":"69","author":"Jansaker","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0924-8579(03)00235-8","article-title":"Pivmecillinam\u2014Therapy of choice for lower urinary tract infection","volume":"22","author":"Graninger","year":"2003","journal-title":"Int. J. Antimicrob. Ag."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ijantimicag.2011.09.013","article-title":"Antimicrobial susceptibility of Escherichia coli from community-acquired urinary tract infections in Europe: The ECO.SENS study revisited","volume":"39","author":"Kahlmeter","year":"2012","journal-title":"Int. J. Antimicrob. Ag."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ijantimicag.2009.04.012","article-title":"The ARESC study: An international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections","volume":"34","author":"Schito","year":"2009","journal-title":"Int. J. Antimicrob. Ag."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s40121-015-0095-5","article-title":"Antimicrobial Resistance of Escherichia coli Causing Uncomplicated Urinary Tract Infections: A European Update for 2014 and Comparison with 2000 and 2008","volume":"4","author":"Kahlmeter","year":"2015","journal-title":"Infect. Dis. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/jac\/dkg280","article-title":"Cross-resistance and associated resistance in 2478 Escherichia coli isolates from the Pan-European ECO.SENS Project surveying the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections","volume":"52","author":"Kahlmeter","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1093\/jac\/dkt159","article-title":"High genetic diversity of nitrofurantoin- or mecillinam-resistant Escherichia coli indicates low propensity for clonal spread","volume":"68","author":"Poulsen","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"761","DOI":"10.2147\/IDR.S163280","article-title":"Mecillinam for the treatment of acute pyelonephritis and bacteremia caused by Enterobacteriaceae: a literature review","volume":"11","author":"Jansaker","year":"2018","journal-title":"Infect. Drug Resist."},{"key":"ref_18","unstructured":"The European Committee on Antimicrobial Susceptibility Testing (2019, April 09). The Epidemiological Cutt-Off Value (ECOFFs). Available online: https:\/\/mic.eucast.org\/Eucast2\/."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/apm.12147","article-title":"Mecillinam resistance and outcome of pivmecillinam treatment in uncomplicated lower urinary tract infection in women","volume":"122","author":"Monsen","year":"2014","journal-title":"APMIS"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/02813430601183074","article-title":"Clinical and bacteriological outcome of different doses and duration of pivmecillinam compared with placebo therapy of uncomplicated lower urinary tract infection in women: The LUTIW project","volume":"25","author":"Ferry","year":"2007","journal-title":"Scand. J. Prim. Health"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3109\/02813432.2015.1041827","article-title":"A randomized controlled trial of a diagnostic algorithm for symptoms of uncomplicated cystitis at an out-of-hours service","volume":"33","author":"Bollestad","year":"2015","journal-title":"Scand. J. Prim. Health"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Vik, I., Bollestad, M., Grude, N., Baerheim, A., Damsgaard, E., Neumark, T., Bjerrum, L., Cordoba, G., Olsen, I.C., and Lindbaek, M. (2018). Ibuprofen versus pivmecillinam for uncomplicated urinary tract infection in women-A double-blind, randomized non-inferiority trial. PLoS MED, 15.","DOI":"10.1371\/journal.pmed.1002569"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1080\/02813430802535312","article-title":"Pivmecillinam versus sulfamethizole for short-term treatment of uncomplicated acute cystitis in general practice: a randomized controlled trial","volume":"27","author":"Bjerrum","year":"2009","journal-title":"Scand. J. Prim. Health"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Jans\u00e5ker, F., Th\u00f8nnings, S., Hertz, F.B., Kallemose, T., V\u00e6rnet, J., Bjerrum, L., Benfield, T., Frimodt-M\u00f8ller, N., and Knudsen, J.D. (2019). Three versus Five Days of Pivmecillinam for Community-Acquired Uncomplicated Lower Urinary Tract Infection: A Randomised, Double-Blind, Placebo-Controlled Superiority Trial. EClinicalMedicine, stage of publication (under review).","DOI":"10.1016\/j.eclinm.2019.06.009"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Jansaker, F., Frimodt-Moller, N., Bjerrum, L., and Dahl Knudsen, J. (2016). The efficacy of pivmecillinam: 3 days or 5 days t.i.d against community acquired uncomplicated lower urinary tract infections - a randomized, double-blinded, placebo-controlled clinical trial study protocol. BMC Infect. Dis., 16.","DOI":"10.1186\/s12879-016-2022-0"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Vik, I., Bollestad, M., Grude, N., Baerheim, A., Molstad, S., Bjerrum, L., and Lindbaek, M. (2014). Ibuprofen versus mecillinam for uncomplicated cystitis--a randomized controlled trial study protocol. BMC Infect. Dis., 14.","DOI":"10.1186\/s12879-014-0693-y"},{"key":"ref_27","unstructured":"The European Committee on Antimicrobial Susceptibility Testing (2019, April 09). Breakpoint Tables for Interpretation of MICs and Zone Diameters. Available online: http:\/\/www.eucast.org."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1046\/j.1198-743x.2001.00237.x","article-title":"European guidelines for urinalysis: a collaborative document produced by European clinical microbiologists and clinical chemists under ECLM in collaboration with ESCMID","volume":"7","author":"Aspevall","year":"2001","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ebiom.2017.08.021","article-title":"Reversion of High-level Mecillinam Resistance to Susceptibility in Escherichia coli During Growth in Urine","volume":"23","author":"Thulin","year":"2017","journal-title":"EBioMedicine"}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/8\/2\/57\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:49:37Z","timestamp":1760186977000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/8\/2\/57"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,7]]},"references-count":29,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,6]]}},"alternative-id":["antibiotics8020057"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics8020057","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,7]]}}}